Enhanced Detection of Early Hepatocellular Carcinoma by Serum SELDI-TOF Proteomic Signature Combined with Alpha-Fetoprotein Marker
Lei Chen(Zhejiang Cancer Hospital), John M. Luk(Paccar (United States)), Brian Lam(University of Cambridge), Eddy Wing Yin Ng(Chinese University of Hong Kong), Zongwei Cai(Hong Kong Baptist University), Stella Sun(University of Pittsburgh), Xi-sheng Leng(Peking University), Nikki P.Y. Lee(University of Hong Kong), Xin Yi(Peking University), George Lau(Humanity & Health), Jirun Peng(Peking University), David W. Ho(Queen Mary Hospital), Ronnie T.P. Poon(Queen Mary Hospital), Kwong‐Fai Wong(National University of Singapore), Terence C. W. Poon(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 49
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895